TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of newly diagnosed or recurrent transitional cell bladder cancer meeting the following criteria:~  * Ta or T1 primary tumor~ * Grade 1 or 2 disease~* No more than 2 recurrences (except for index tumor) within the 18 months prior to the index tumor's transurethral resection of the bladder tumor (TURBT)~  * Index tumor post-TURBT must meet the following criteria:~    * Ta or T1 tumor without any prior tumor in situ, grade 3 (high grade) disease within 2 years prior to index tumor TURBT, or invasion of the muscularis propria (stage ≥ T2)~   * Grade 1 or 2 disease (similar to papillary urothelial neoplasm of low malignant potential and low-grade bladder cancer)~* Not a candidate for a therapy other than TURBT (e.g., a series of instillations of intravesical immunotherapy \[e.g., BCG\] or intravesical chemotherapy, or cystectomy or partial cystectomy)~* Negative upper tract imaging studies within 1 year (365 days) prior to study entry~  * Imaging studies may be performed after registration provided it is done prior to TURBT on the day of treatment~* No urothelial cancer of the prostate or more distal urethra (or urethra at all in women) as assessed by endoscopy~* Must have a negative urine culture (less than or equal to 10,000 col/mL, mixed flora-likely contamination) OR negative urine analysis for infection AND negative nitrates on reagent strip, ≤ 10 white blood cell count (WBC)/high-power field, and no rods or organisms on examination of spun urine sediment OR an automated or visual reagent strip urinalysis that is negative for leukocytes and nitrates within the past 28 days~* TURBT planned within the next 28 days and planned treatment within 3 hours after TURBT~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy except for any of the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * In situ cervical cancer~ * Adequately treated stage I or II cancer from which patient is in complete remission~ * Any other cancer from which patient has been disease-free for 3 years~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 145 days since prior intravesical therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive intravesical gemcitabine hydrochloride over 1 hour.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive intravesical placebo over 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is scheduled for elective major abdominal surgery and has two or more risk factors according to the Lee classification scheme.~* Patient can sign informed consent before surgery.~* Patient is able to comply with the study procedure.~* Patient must require an indwelling radial or a femoral artery catheter.~* Patient must be 20 years old or older.~* Patient must be 40kg or heavier.~* Patients height and weight can be accurately obtained prior to study start.~Exclusion Criteria:~* Emergency surgery.~* Patients with aortic or mitral valve regurgitation.~* Renal insufficiency requiring hemodialysis.~* Liver dysfunction (alanine/aspartate aminotransferase \>40 U/L).~* Patient with contraindications for the placement of radial, femoral or other arterial cannulae.~* Patient being treated with an intraaortic balloon pump.~* Female patients with a known pregnancy.~* Patient is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed lung cancer, excluding small cell carcinoma~* Inoperable stage I (T1-2N0) and II (T1-2N1, T3N0) disease, or stage IIIA (T3N1 andT1-3N2M0) and IIIB (TxN3M0, T4NxM0) diseases according to the American Joint Committee of Cancer criteria 1998~* The primary tumor must be radiographically measurable.~* Age \> 18.~* Karnofsky performance status \> 70.~* FEV1 sufficient for patients to tolerate radiation therapy which is at the discretion of the radiation oncologist, usually \> 800 ml~* Labs: WBC \> 3000; platelet count \> 100,000; serum creatinine \< 1.5 mg/dl or creatinine clearance \>60 ml/min.~* Laboratory values must be obtained \< 3 weeks prior to registration.~* A signed informed consent.~* Patients who failed prior chemotherapy are eligible. Patients with prior radiotherapy to the chest region are eligible as long as the normal tissue tolerance is not violated by repeat radiotherapy.~Exclusion Criteria:~* Patients with medical contraindication to chemotherapy or radiotherapy.~* Patients with myocardial infarction within the preceding six months or symptomatic heart disease, including uncontrolled or unstable angina, uncontrolled congestive heart failure, and uncontrolled arrhythmia.~* Women who are pregnant.~* Patients with small cell carcinoma or mesothelioma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1st dose cohort 15mg/m2 taxol plus RT (Type: EXPERIMENTAL): 15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
- 2nd dose cohort20 mg/m2 taxol plus daily RT (Type: EXPERIMENTAL): None
- 3rd Dose Cohort --25mg/m2 taxol plus RT (Type: EXPERIMENTAL): None
- Phase II Arm --20mg/m2 taxol plus RT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid-induced Hyperalgesia After Remifentanil Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18-60~* Body mass index 17-30~* Healthy volunteers~Exclusion Criteria:~* Use of medication; alternative medicine~* Substance abuse~* Allergies towards medication used in the study~* Participation in other clinical studies the previous 6 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Remifentanil (Type: EXPERIMENTAL): The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: World Maternal Antifibrinolytic Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
All legally adult women with postpartum haemorrhage following vaginal or caesarean section delivery who have a clinical diagnosis of postpartum haemorrhage. The clinical diagnosis of PPH may be based on any of the following:~* Blood loss after vaginal delivery \> 500 mL OR~* \> 1,000 mL after caesarean section OR blood loss sufficient to compromise the haemodynamic status of the woman The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular woman with postpartum haemorrhage.~* Women for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy should not be randomised.~* Women for whom there is considered to be a clear contraindication to antifibrinolytic therapy should not be randomised.~Where the responsible clinician is substantially uncertain as to whether or not to use an antifibrinolytic, all these women are eligible for randomisation and should be considered for the trial.~There are no other pre-specified exclusion criteria.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with nAMD that were treated with intravitreal injection of anti-VEGF and had a minimum follow up of 48 months~Exclusion Criteria:~* Loss follow over 1 year.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QLB vs. Wound Infiltration in Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parturients scheduled for an elective caesarean delivery under spinal anaesthesia with an American Society of Anesthesiologists physical status I or II, singleton pregnancy, and gestational age ≥ 37 completed weeks.~Exclusion Criteria:~* Congenital or acquired coagulopathy.~* Allergy to local anaesthetics.~* History of drug abuse.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Quadratus Lumborum Block type 2 (Type: EXPERIMENTAL): The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
- Wound Infiltration (Type: ACTIVE_COMPARATOR): Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis Satisfaction Outcome Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 19 years or older~2. Patients diagnosed with RA~3. Treatment groups:~1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough proficiency to complete assessment instruments in Korean~Exclusion Criteria:~1. Patients currently on tofacitinib citrate or adalimumab for 2 year or more~2. Patients taking Azathioprine and cyclosporine~3. Patients participating in other drug interventional study~4. Patients who have been treated with bDMARDs except Rheumatoid arthritis.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tofacitinib citrate users (Type: None): patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
- adalimumab users (Type: None): patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Level Laser Therapy to Reduce Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muscular-skeletal pain in the neck/shoulder region~* Acute and chronic pain in the neck/shoulder region~* Restricted range of motion in the neck/shoulder region~* Fibrosis or scar tissue in the neck/shoulder region~* Inflammation in the neck/shoulder region~* Altered function in the neck/shoulder region~* Muscle strains in the neck/shoulder region~* Rating of 30 or greater on the 0-100 Visual Analog Scale (VAS) pain scale~* 18-65 years of age~Exclusion Criteria:~* Severely herniated disks~* Pregnancy~* Taken pain medication within the past 12 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erchonia PL2000 Laser (Type: ACTIVE_COMPARATOR): Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
- Placebo laser (Type: PLACEBO_COMPARATOR): inactive light

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants undergoing microsurgical testicular sperm extraction.~* Participants over 18 years of age who can provide informed consent~* Participants with no contraindication to the consumption gabapentin or documented allergy/intolerance~* Participants not currently using opiates for another reason~Exclusion Criteria:~* Contraindication to the consumption of celecoxib or gabapentin~* History of substance abuse (including prior opiate abuse)~* Narcotic use within last 3 months~* Any of the following comorbidities: renal failure, heart disease, peptic ulcer disease, cerebrovascular disease, significant liver disease, untreated depression, chronic pain disorder, or bleeding diatheses~* Medical history or concurrent illness that the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this trial, or constitutes an unacceptable risk to the subject

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically confirmed relapsed CNS lymphoma~  * Arising from primary CNS lymphoma or systemic non-Hodgkin's lymphoma~* Evidence of brain parenchymal involvement, cerebrospinal fluid (CSF) involvement, or ocular involvement after radiation treatment or intrathecal chemotherapy~* Tumors must be CD20+ on pathologic analysis~* Refractory or persistent disease allowed~* No complete obstruction of the CSF pathway within the ventricular system unless alleviated by external beam radiotherapy or systemic chemotherapy~* No obstructive hydrocephalus~PATIENT CHARACTERISTICS:~* Karnofsky performance status \> 50%~* Must have an Ommaya reservoir~* Granulocyte count \> 1,500/mm\^3~* Platelet count \> 50,000/mm\^3~* Anticipated survival ≥ 1 month~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from toxicity of prior therapy~* Prior intrathecal methotrexate, cytarabine, or thiotepa for CNS lymphoma allowed~* Concurrent systemic chemotherapy for treatment of disease outside meninges allowed except for high-dose methotrexate, high-dose cytarabine, high-dose thiotepa, or investigational agents~* No history of whole-brain or craniospinal radiation \< 1 week before study entry~* No history of intrathecal chemotherapy \< 1 week before study entry~* No concurrent intrathecal chemotherapy

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal rituximab (Type: EXPERIMENTAL): 3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory~* Last IV bisphosphonate treatment must be \>/= to 7 days and \</= to 30 days before the screening corrected serum calcium~* Adults (\>/=18 years)~* Adequate organ function as defined by the following criteria:~* serum aspartate aminotransferase (AST) \</= 5 x upper limit of normal (ULN)~* serum alanine aminotransferase (ALT) \</= 5 x upper limit of normal~* serum total bilirubin \</= 2 x upper limit of normal~Exclusion Criteria:~* Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease~* Receiving dialysis for renal failure~* Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC~* Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC~* Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study~* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)~* Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment~* Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment~* Subject will not be available for follow-up assessment.~* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab (Type: EXPERIMENTAL): Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ADA-SCID with no HLA-identical sibling donor available~* pediatric age and at least one of the following criteria:~* inadequate immune response after PEG-ADA for \> 6 months~* patients who discontinued PEG-ADA due to intolerance, allergy or auto-immunity~* patients for whom enzyme replacement therapy is not a life long therapeutic option~Exclusion Criteria:~* HIV infection~* history or current malignancy~* Patients who received a previous gene therapy treatment in the 12 months prior to receiving Strimvelis~* any other conditions dangerous for the patients according to the investigator

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Gene Therapy (Type: EXPERIMENTAL): Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete